Nasdaq
$28.00▲ 0.09%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $2.01BShares out 71.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
14- 9.17After-hours26.09.18 05:284Ownership#●●●#●●●
Vera Therapeutics, Inc.
Insider Marshall Fordyce of Vera Therapeutics reported a change in beneficial ownership of company securities on September 15, 2026. This filing serves as a Form 4 notification regarding the insider's equity holdings.…more
$28.00+0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.15Pre-market26.09.15 19:458-KKey event
Vera Therapeutics, Inc.
Vera Therapeutics announced that TRUTAKNA successfully met all primary and key secondary efficacy endpoints in the Phase 3 ORIGIN 3 trial for patients with IgA nephropathy. The results demonstrated significant stabilization of eGFR and a reduction in kidney disease progression, supporting the company's plan to submit a supplemental BLA to the FDA in Q4 2026.…more
$28.00+0.09%vs prev closeView filingShare - 9.14After-hours26.09.15 05:284Ownership
Vera Therapeutics, Inc.
Insider Joseph R. Young of Vera Therapeutics, Inc. filed a Form 4 report on September 14, 2026, disclosing changes in beneficial ownership of securities as of September 11, 2026.…more
$28.00+0.09%vs prev closeView filingShare
13 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 2d agoRegular26.10.22 23:06Bullish#●●●#●●●#●●●
Vera Therapeutics Announces Positive Phase 3 Results for TRUTAKNA
Vera Therapeutics' TRUTAKNA met its primary endpoint of proteinuria reduction in the Phase 3 ORIGIN 3 study for IgA nephropathy. The results were published in the New England Journal of Medicine and presented at the ASN Kidney Week conference.…more
$28.00+0.09%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 5d agoPre-market26.10.20 21:00
●●●●●●●● ●●●●● ●●●●●●
Vera Therapeutics will host investor webcasts to discuss the final efficacy results of the TRUTAKNA ORIGIN 3 clinical trial and its third-quarter 2026 financial results. These sessions will provide key updates on clinical data and the company's business progress.…more
$28.00+0.09%vs prev close - 10.2After-hours26.10.03 05:05
●●●●●●●● ●●●●● ●●●●●●
Vera Therapeutics has granted stock options and restricted stock units to five new employees as an inducement for their hiring under Nasdaq rules. This is a standard compensation practice for talent acquisition and does not impact the company's financial performance.…more
$28.00+0.09%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report